Answers are grounded in this paper and cite their sources.
This study met its primary end point, with an ORR of 38% (P < .0001) in this mixed histology, pretreated cohort. This promising activity warrants additional investigations in BRAFV600-mutated tumors outside of currently approved indications.
No takes yet. Share an insight, caveat, or question.
Salama et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: